Patients need an antidepressant that helps alleviate their depression and DOESN’T cause side effects that impact their quality of life.

Common debilitating side effects of antidepressants on the market.

Sexual Dysfunction

Common debilitating side effects of antidepressants on the market.

Weight Gain

Common debilitating side effects of antidepressants on the market.

Initial feelings of increased anxiety and agitation.

EXXUA™ is believed to work by targeting 5HT1a receptor and not other serotonin receptors, therefore not causing side effects like most antidepressants currently on the market.

Exxua™ for MDD

Identify, develop and commercialize psychotropic drugs

Fabre-Kramer (Fabre-Kramer Pharmaceuticals, Inc.) development program features more efficient outsourced structure and accelerated timelines. FKP can economically and efficiently further develop these products, and then out-license them for the completion of development, registration, and commercialization. FKP has developed its pipeline of pharmaceutical products at costs far below those of major pharmaceutical companies.

Learn More About Fabre-Kramer


Fabre-Kramer Products focus on the development of psychiatry and neurology. The pipeline consists of EXXUA™, FKO1MDD, FKBO1MD, FKWOOG, FKFO2SC, and FKFO1PD products majority of which are in advanced clinical development. The lead compound EXXUA™ expects approval in 2023.

Learn More About the Pipeline


As a virtual company, FKP forms partnerships with individual researchers, research institutions,
pharmaceutical as well as biotechnology companies, to license in molecules for development and further license them out for commercialization.

Fabre-Kramers expertise is concentrated around clinical development of compounds in the area of psychiatry and neurology.

Learn More About Partnerships